IGI Laboratories Announces Second Quarter 2015 Results

Go back to IGI Laboratories Announces Second Quarter 2015 Results

Roth Capital Upgrades IGI Laboratories (IG) to Buy; Sees 2016 at Break-Out Year

July 24, 2015 6:58 AM EDT

Roth Capital upgraded IGI Laboratories (NYSE: IG) from Neutral to Buy with a price target of $11.00 (from $7.00), saying 2016 could be a break-out year.

Analyst Scott Henry commented, "The impetus for our upgrade is stabilization of the econazole nitrate franchise, a lower valuation, and... More

IGI Labs (IG) Tops Q2 EPS by 4c

July 23, 2015 4:25 PM EDT

IGI Labs (NYSE: IG) reported Q2 EPS of ($0.04), $0.04 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $8.9 million versus the consensus estimate of $7.63 million.

IGI Labs reaffirmed FY2015 guidance.

IGI's President and Chief Executive Officer, Jason Grenfell-Gardner, stated, "We are pleased with our steady progress this quarter. On the regulatory front, we received the FDA's final approval for our diclofenac sodium 1.5%... More